{"id":"NCT00243659","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","briefTitle":"Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery","officialTitle":"An Open Label Multi-center Study to Assess the Efficacy and Safety of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-04","primaryCompletion":"2008-06","completion":"2008-06","firstPosted":"2005-10-24","resultsPosted":"2009-07-20","lastUpdate":"2011-06-03"},"enrollment":30,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia A"],"interventions":[{"type":"BIOLOGICAL","name":"ReFacto AF","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"EXPERIMENTAL"}],"summary":"This study will examine the efficacy and safety of ReFacto AF in patients with severe and moderately severe hemophilia A undergoing elective major surgery when administered by either bolus injections (BI) or continuous infusion (CI).","primaryOutcome":{"measure":"Number of Patients Who Achieved Hemostatic Efficacy After Surgery","timeFrame":"6 weeks","effectByArm":[{"arm":"Bolus Injection","deltaMin":15,"sd":null},{"arm":"Continuous Infusion","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":17,"countries":["United States","Australia","Austria","Hungary","New Zealand","Poland","Romania","Sweden"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4},"commonTop":["Fever","Anemia","Pain","Injection","Headache"]}}